1.Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study
Jee Woong CHOI ; Yul Hee KIM ; Hyunbin KWAK ; Jin PARK ; Won-Soo LEE ; Hoon KANG ; Jung Eun KIM ; Tae-Young YOON ; Ki-Ho KIM ; Yong Hyun JANG ; Do Won KIM ; Moon-Bum KIM ; Bark-Lynn LEW ; Woo-Young SIM ; Jiehyun JEON ; Soo Hong SEO ; Ohsang KWON ; Chang-Hun HUH ; Dong-Youn LEE ; Yang Won LEE ; Byung Choel PARK ; Chong Hyun WON ; Do Young KIM ; Hyojin KIM ; Beom Joon KIM ; Young LEE ; Sang Seok KIM ; Gwang Seong CHOI ; The Korean Hair Research Society
Annals of Dermatology 2022;34(4):237-244
Background:
Pediatric alopecia areata (AA) can affect the quality of life (QoL) of patients and their family members. Research on the QoL and burden on family members in pediatric AA is limited.
Objective:
This nationwide multicenter questionnaire study described the QoL and burden of the family members of patients with pediatric AA.
Methods:
This nationwide multicenter questionnaire study enrolled AA patients between the ages of 5 and 18 years from March 1, 2017 to February 28, 2018. Enrolled patients and their parents completed the modified Children’s Dermatology Life Quality Index (CDLQI) and the modified Dermatitis Family Impact (mDFI). The disease severity was measured using the Severity of Alopecia Tool (SALT) survey scores.
Results:
A total of 268 patients with AA from 22 hospitals participated in this study. Our study found that the efficacy and satisfaction of previous treatments of AA decreased as the severity of the disease increased. The use of home-based therapies and traditional medicines increased with the increasing severity of the disease, but the efficacy felt by patients was limited. CDLQI and mDFI scores were higher in patients with extensive AA than those with mild to moderate AA. The economic and time burden of the family members also increased as the severity of the disease increased.
Conclusion
The severity of the AA is indirectly proportional to the QoL of patients and their family members and directly proportional to the burden. Physicians need to understand these characteristics of pediatric AA and provide appropriate intervention to patients and their family members.
2.A comparative study of the clinical characteristics and outcomes of HR-positive HER2-negative breast cancer patients over and under 65 years old
Chang Shin JUNG ; Youn Joo JUNG ; Dong Il KIM ; Seungju LEE ; Seok Kyung KANG ; Su Bong NAM ; Hyun Yul KIM
Korean Journal of Clinical Oncology 2021;17(1):1-7
Purpose:
The purpose of this study was to compare the clinical characteristics and outcomes of hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2–) breast cancer among elderly patients (over 65 years old) and younger patients.
Methods:
This was a retrospective cohort study of 328 patients who were treated for breast cancer at Pusan National University Yangsan Hospital between January 2009 and December 2014. Tumor characteristics, surgical methods, and survival outcomes were compared between the two age groups (<65 and ≥65 years old). Kaplan-Meier curves for disease-free survival (DFS) and overall survival (OS) were also constructed according to the age groups.
Results:
Among the 328 patients with HR+ HER2– breast cancer, 184 (56.1%) were <65 years old and 144 (43.9%) were ≥65 years old. Breast cancer stages were similar between the two age groups, but the older patients were treated less often with chemotherapy (81% vs. 66%, P=0.002). During the follow-up period, 17 deaths and 36 cases of recurrence or metastasis were reported. There was no difference in DFS between the two groups (P=0.840); however, the OS of the older age group was significantly lower than that of the younger age group (P=0.015).
Conclusion
This study suggested that HR+ HER2– breast cancer patients belonging to the two age groups had no significant difference in DFS. However, older age is an independent factor affecting OS rate. Therefore, even if patients are old, but their physical condition is satisfactory, standard and active treatment may be necessary, similar to that given to younger patients.
3.A comparative study of the clinical characteristics and outcomes of HR-positive HER2-negative breast cancer patients over and under 65 years old
Chang Shin JUNG ; Youn Joo JUNG ; Dong Il KIM ; Seungju LEE ; Seok Kyung KANG ; Su Bong NAM ; Hyun Yul KIM
Korean Journal of Clinical Oncology 2021;17(1):1-7
Purpose:
The purpose of this study was to compare the clinical characteristics and outcomes of hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2–) breast cancer among elderly patients (over 65 years old) and younger patients.
Methods:
This was a retrospective cohort study of 328 patients who were treated for breast cancer at Pusan National University Yangsan Hospital between January 2009 and December 2014. Tumor characteristics, surgical methods, and survival outcomes were compared between the two age groups (<65 and ≥65 years old). Kaplan-Meier curves for disease-free survival (DFS) and overall survival (OS) were also constructed according to the age groups.
Results:
Among the 328 patients with HR+ HER2– breast cancer, 184 (56.1%) were <65 years old and 144 (43.9%) were ≥65 years old. Breast cancer stages were similar between the two age groups, but the older patients were treated less often with chemotherapy (81% vs. 66%, P=0.002). During the follow-up period, 17 deaths and 36 cases of recurrence or metastasis were reported. There was no difference in DFS between the two groups (P=0.840); however, the OS of the older age group was significantly lower than that of the younger age group (P=0.015).
Conclusion
This study suggested that HR+ HER2– breast cancer patients belonging to the two age groups had no significant difference in DFS. However, older age is an independent factor affecting OS rate. Therefore, even if patients are old, but their physical condition is satisfactory, standard and active treatment may be necessary, similar to that given to younger patients.
4.Are the Outcomes of Breast Conservation Surgery Inferior to Those of Mastectomy in Patients with Stage II-IIIA Triple-Negative Breast Cancer?
Seungju LEE ; Hyun Yul KIM ; Youn Joo JUNG ; Hyun-June PAIK ; Dong-Il KIM ; Chang Shin JUNG ; Seok-Kyung KANG ; Jee Yeon KIM ; Seokwon LEE ; Youngtae BAE
Journal of Breast Disease 2021;9(2):77-83
Purpose:
Breast conserving surgery (BCS) is generally not considered for breast cancer because of concerns about the poor prognosis of triple negative breast cancer (TNBC). We assessed the outcomes of BCS and mastectomy for patients with stage II-IIIA TNBC.
Methods:
The data of 172 breast cancer patients diagnosed with stage II-IIIA TNBC who underwent treatment at Pusan National University Hospital and Pusan National University Yangsan Hospital from 2010 to 2014 were retrospectively analyzed. The patients were divided into the following two groups: patients who underwent BCS (n=101) and those who underwent mastectomy (n=71). The Cox regression model was used to examine the outcomes of both treatments. The median follow-up period was 71 months in the BCS group, and 67 months in the mastectomy group.
Results:
The median age of the 172 patients was 51 years (range, 22-82 years). In the BCS group, radiation therapy and chemotherapy (p<0.001 and p=0.007, respectively) were performed more frequently. The BCS group had more patients with a high Ki-67 index (p=0.006), while the mastectomy group included more patients with a higher pathologic T (pT) stage (p=0.005). The 5-year loco-regional recurrence-free, disease-free, and overall survival rates of the BCS group versus the mastectomy group were 93.8% versus 95.3%, 89.8% versus 90.7%, and 90.8% versus 86.3%, respectively, but the differences were not statistically significant. Lymphovascular invasion was a risk factor for disease-free survival and advanced stage was an important risk factor for overall survival.
Conclusion
In stage II-IIIA TNBC, BCS was not inferior to mastectomy in locoregional recurrence rates, disease-free survival rates, or overall survival rates.
5.Thyrotropin suppression therapy for papillary thyroid carcinoma with a huge recurred neck lymph node
Jung Bum CHOI ; Dong-il KIM ; Hyun-june PAIK ; Seung Joo LEE ; Chang Shin JUNG ; Seok Kyung KANG ; Youn Joo JUNG ; Hyun Yul KIM
Korean Journal of Clinical Oncology 2020;16(2):145-147
Differentiated thyroid cancer (DTC) originating from thyroid tissue is affected by thyrotropin (TSH). TSH suppression therapy is usually recommended after thyroidectomy in cases of DTC. A 57-year-old woman who harbored a very huge recurred lymph node underwent TSH suppression therapy because of the risk of surgical complications. After TSH suppression, the huge neck lymph node exhibited a response and decreased in size. She had been followed up for 144 months. TSH suppression therapy could be considered as an alternative treatment option in a recurred DTC patient with a high perioperative risk.
6.Thyrotropin suppression therapy for papillary thyroid carcinoma with a huge recurred neck lymph node
Jung Bum CHOI ; Dong-il KIM ; Hyun-june PAIK ; Seung Joo LEE ; Chang Shin JUNG ; Seok Kyung KANG ; Youn Joo JUNG ; Hyun Yul KIM
Korean Journal of Clinical Oncology 2020;16(2):145-147
Differentiated thyroid cancer (DTC) originating from thyroid tissue is affected by thyrotropin (TSH). TSH suppression therapy is usually recommended after thyroidectomy in cases of DTC. A 57-year-old woman who harbored a very huge recurred lymph node underwent TSH suppression therapy because of the risk of surgical complications. After TSH suppression, the huge neck lymph node exhibited a response and decreased in size. She had been followed up for 144 months. TSH suppression therapy could be considered as an alternative treatment option in a recurred DTC patient with a high perioperative risk.
7.Low-Dose Abdominal CT Using a Deep Learning-Based Denoising Algorithm: A Comparison with CT Reconstructed with Filtered Back Projection or Iterative Reconstruction Algorithm
Yoon Joo SHIN ; Won CHANG ; Jong Chul YE ; Eunhee KANG ; Dong Yul OH ; Yoon Jin LEE ; Ji Hoon PARK ; Young Hoon KIM
Korean Journal of Radiology 2020;21(3):356-364
OBJECTIVE: To compare the image quality of low-dose (LD) computed tomography (CT) obtained using a deep learning-based denoising algorithm (DLA) with LD CT images reconstructed with a filtered back projection (FBP) and advanced modeled iterative reconstruction (ADMIRE).MATERIALS AND METHODS: One hundred routine-dose (RD) abdominal CT studies reconstructed using FBP were used to train the DLA. Simulated CT images were made at dose levels of 13%, 25%, and 50% of the RD (DLA-1, -2, and -3) and reconstructed using FBP. We trained DLAs using the simulated CT images as input data and the RD CT images as ground truth. To test the DLA, the American College of Radiology CT phantom was used together with 18 patients who underwent abdominal LD CT. LD CT images of the phantom and patients were processed using FBP, ADMIRE, and DLAs (LD-FBP, LD-ADMIRE, and LD-DLA images, respectively). To compare the image quality, we measured the noise power spectrum and modulation transfer function (MTF) of phantom images. For patient data, we measured the mean image noise and performed qualitative image analysis. We evaluated the presence of additional artifacts in the LD-DLA images.RESULTS: LD-DLAs achieved lower noise levels than LD-FBP and LD-ADMIRE for both phantom and patient data (all p < 0.001). LD-DLAs trained with a lower radiation dose showed less image noise. However, the MTFs of the LD-DLAs were lower than those of LD-ADMIRE and LD-FBP (all p < 0.001) and decreased with decreasing training image dose. In the qualitative image analysis, the overall image quality of LD-DLAs was best for DLA-3 (50% simulated radiation dose) and not significantly different from LD-ADMIRE. There were no additional artifacts in LD-DLA images.CONCLUSION: DLAs achieved less noise than FBP and ADMIRE in LD CT images, but did not maintain spatial resolution. The DLA trained with 50% simulated radiation dose showed the best overall image quality.
Artifacts
;
Humans
;
Noise
;
Tomography, X-Ray Computed
8.Frenkel’s exercise on lower limb sensation and balance in subacute ischemic stroke patients with impaired proprioception
Eun Jae Ko ; Min Ho Chun ; Dae-Yul Kim ; Yujeong Kang ; Sook Joung Lee ; Jin Hwa Y ; Min Cheol Chang ; So Young Lee
Neurology Asia 2018;23(3):217-224
Few reliable studies have used standardized outcome measures to examine
the effectiveness of sensory interventions to treat somatosensory impairment. The aim of this study is
to examine the effectiveness of Frenkel’s exercise for improving lower limb sensation, balance, motor
function, functional ambulation, and activities of daily living in subacute ischemic stroke patients with
impaired proprioception. Methods: This retrospective cohort study enrolled 14 patients suffering subacute
ischemic stroke between 7 to 30 days of onset who showed reduced proprioception in the lower limbs.
They were divided into two groups: intervention group (performed Frenkel’s exercise, 15 minutes per
day, 15 days over a period of 3 weeks, n=7) and control group (received conventional physical therapy
instead, n=7). Outcome measurements included the kinesthetic and light touch sensation subscales of the
Nottingham Sensory Assessment (NSA) for the lower limb, the Korean version of the Berg balance scale
(K-BBS), the Functional Ambulation Classification (FAC), the Motricity Index (MI), and the Korean
version of the Modified Barthel Index (K-MBI). Results: Patients in both groups showed significant
improvements on the kinesthetic and tactile sensation subscale of the NSA for the lower limb, the K-BBS,
the FAC, and the K-MBI, but not the MI, from baseline to post-intervention at 3 weeks. When compared
between the two groups, significant improvements were only seen in the kinesthetic sensation subscale
of the NSA for the lower limb and the K-BBS (p<0.05).
Conclusions: Frenkel’s exercise improves sensory and balance recovery among subacute ischemic stroke
patients with impaired proprioception and minimal lower limb motor weakness.
9.A portable high-intensity focused ultrasound system for the pancreas with 3D electronic steering: a preclinical study in a swine model.
Won CHANG ; Jae Young LEE ; Jae Hwan LEE ; Jae Seok BAE ; Yeon Jin CHO ; Kook Jin KANG ; Keonho SON ; Yul Ri CHUNG ; Kyoung Bun LEE ; Joon Koo HAN
Ultrasonography 2018;37(4):298-306
PURPOSE: The aim of this animal study was to evaluate the safety and feasibility of a portable, ultrasonography-guided, high-intensity focused ultrasound (USg-HIFU) system to treat the pancreas. METHODS: Eight swine were included. Using a portable HIFU device (ALPIUS 900, Alpinion Medical Systems), ablations were performed on the pancreas in vivo. Different acoustic intensities were applied (1.7 kW/cm2 or 1.5 kW/cm2, n=2 [group A for a pilot study]; 1.5 kW/ cm2, n=3 [group B]; and 1.2 kW/cm2, n=3 [group C]). Magnetic resonance imaging (MRI) was performed immediately (group A) or 7 days (groups B and C) after HIFU treatment. In groups B and C, serum amylase and lipase levels were measured on days 0 and 7, and performance status was observed every day. Necropsy was performed on days 0 (group A) or 7 (groups B and C) to assess the presence of unintended injuries and to obtain pancreatic and peripancreatic tissue for histological analysis. RESULTS: Ablation was noted in the pancreas in all swine on MRI, and all pathologic specimens showed coagulation necrosis in the treated area. The mean ablation areas on MRI were 85.3±38.1 mm2, 90.7±21.2 mm2, and 54.4±30.6 mm2 in groups A, B, and C, respectively (P>0.05). No animals showed evidence of complications, except for one case of a pseudocyst in group B. CONCLUSION: This study showed that pancreas ablation using a portable USg-HIFU system may be safe and feasible, and that coagulation necrosis of the pancreas was successfully achieved with a range of acoustic intensities.
Acoustics
;
Amylases
;
Animal Experimentation
;
Animals
;
Lipase
;
Magnetic Resonance Imaging
;
Necrosis
;
Pancreas*
;
Swine*
;
Ultrasonography*
10.Bioresorbable Vascular Scaffold Korean Expert Panel Report.
Jung Min AHN ; Duk Woo PARK ; Sung Jin HONG ; Young Keun AHN ; Joo Yong HAHN ; Won Jang KIM ; Soon Jun HONG ; Chang Wook NAM ; Do Yoon KANG ; Seung Yul LEE ; Woo Jung CHUN ; Jung Ho HEO ; Deok Kyu CHO ; Jin Won KIM ; Sung Ho HER ; Sang Wook KIM ; Sang Yong YOO ; Myeong Ki HONG ; Seung Jea TAHK ; Kee Sik KIM ; Moo Hyun KIM ; Yangsoo JANG ; Seung Jung PARK
Korean Circulation Journal 2017;47(6):795-810
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.
Coronary Disease
;
Drug Liberation
;
Drug-Eluting Stents
;
Humans
;
Korea
;
Stents
;
Thrombosis


Result Analysis
Print
Save
E-mail